The results of the present study fit with the results of Rauch et al. [26] who indicated that linagliptin was well-tolerated and significantly suppressed the plasma DPP-4 activity in T2DM patients, resulting in immediate enhancements in incretin levels, glucagon suppression, and glycemic management that lasted throughout the study. Here, DPP4 is linked to type 2 diabetes mellitus.